Literature DB >> 31499192

Role of polypyrimidine tract-binding protein 1/yin yang 2 signaling in regulating vascular smooth muscle cell proliferation and neointima hyperplasia.

Zhen Wang1, Xueqing Gan2, Chenming Qiu2, Dachun Yang2, Xiongshan Sun3, Zhi Zeng4.   

Abstract

Abnormal proliferation of vascular smooth muscle cells (VSMCs) is a hallmark of vascular restenosis. We investigated whether polypyrimidine tract-binding protein 1 (PTBP1), a novel regulator of cell proliferation and differentiation, is implicated in VSMC proliferation and neointima hyperplasia responding to injury. C57BL/6 J mice of 10-12 weeks old were randomly divided into sham and carotid artery injury group. Primary VSMCs obtained from thoracic aortas of 10- to 12-week-old mice were treated with physiological saline and platelet derived growth factor-BB (PDGF-BB). Adenovirus expressing shCon, shPTBP1 or shYY2 were transfected into the injured common carotid artery or VSMCs. qRT-PCR and immunoblotting were used to determine the mRNA and protein expression levels, respectively. Immunohistochemical staining of H&E and Ki-67 were used to evaluate restenosis of vessels. Cell counting kit-8 assay and Ki-67 immunofluorescent staining were utilized to evaluate the rate of VSMC proliferation. The expression of PTBP1 were upregulated both in injured arteries and in PDGF-BB-treated VSMCs. PTBP1 inhibition significantly attenuated neointima hyperplasia and Ki-67 positive area induced by injury. Knockdown of PTBP1 in vitro also suppressed VSMC proliferation after PDGF-BB treatment. The effects of PTBP1 inhibition mentioned above were all abolished by knockdown of YY2. Finally, we identified four cell cycle regulators (p53, p21, Cdkn1c, Cdkn2b) that were regulated by PTBP1/YY2 axis both in vitro and in vivo. These findings demonstrated that PTBP1 is a critical regulator of VSMC proliferation and neointima hyperplasia via modulating the expression of YY2.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neointima hyperplasia; PTBP1; VSMC proliferation; YY2; vascular restenosis

Mesh:

Substances:

Year:  2019        PMID: 31499192     DOI: 10.1016/j.taap.2019.114747

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

1.  NF2 deficiency accelerates neointima hyperplasia following vascular injury via promoting YAP-TEAD1 interaction in vascular smooth muscle cells.

Authors:  Xiongshan Sun; Shuang Li; Xueqing Gan; Ken Chen; Dachun Yang; Yongjian Yang
Journal:  Aging (Albany NY)       Date:  2020-05-18       Impact factor: 5.682

2.  Plin5 inhibits proliferation and migration of vascular smooth muscle cell through interacting with PGC-1α following vascular injury.

Authors:  Xueqing Gan; Jiaqi Zhao; Yingmei Chen; Yong Li; Bing Xuan; Min Gu; Feifei Feng; Yongjian Yang; Dachun Yang; Xiongshan Sun
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  Homeostasis Imbalance of YY2 and YY1 Promotes Tumor Growth by Manipulating Ferroptosis.

Authors:  Yanjun Li; Juan Li; Zhuolin Li; Mankun Wei; Hezhao Zhao; Makoto Miyagishi; Shourong Wu; Vivi Kasim
Journal:  Adv Sci (Weinh)       Date:  2022-03-04       Impact factor: 17.521

4.  Tobacco Smoking Increases Methylation of Polypyrimidine Tract Binding Protein 1 Promoter in Intracranial Aneurysms.

Authors:  Zhepei Wang; Shengjun Zhou; Jikuang Zhao; Sheng Nie; Jie Sun; Xiang Gao; Cameron Lenahan; Zhiqin Lin; Yi Huang; Gao Chen
Journal:  Front Aging Neurosci       Date:  2021-07-06       Impact factor: 5.750

5.  Inhibition of PIKfyve Ameliorates the Proliferation and Migration of Vascular Smooth Muscle Cells and Vascular Intima Hyperplasia By Reducing mTORC1 Activity.

Authors:  Min Gu; Zhen Wang; Feifei Feng; Yongjian Yang; Xiongshan Sun; Dachun Yang
Journal:  J Cardiovasc Pharmacol       Date:  2022-05-01       Impact factor: 3.271

Review 6.  Biological roles of Yin Yang 2: Its implications in physiological and pathological events.

Authors:  Lang Li; Yanjun Li; Ian Timothy Sembiring Meliala; Vivi Kasim; Shourong Wu
Journal:  J Cell Mol Med       Date:  2020-09-23       Impact factor: 5.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.